RenovaCare, BCRT enter R&D partnership
RenovaCare, a New York-based human organ regeneration developer, and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals, have partnered to validate the science behind technology for treatments of wounds, burns and other skin defects.
The BCRT focuses on enhancing endogenous regeneration by cells, biomaterials and factors, which can be used to develop and implement innovative therapies and products. RenovaCare is the developer of the patented CellMist and SkinGun technologies for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing.
The objective of the research partnership is to evaluate protocols, methods and outcomes related to the use of the RenovaCare proprietary SkinGun. That process includes better understanding the ability of delicate stem cells to survive and grow after being gently sprayed through SkinGun on to targeted body sites. Survival of those cells is vital to wound healing and recovery.
According to RenovaCare engineers, the company’s proprietary SkinGun spray device is the world’s most advanced technology of its kind, using an ultra-gentle non-turbulent air stream to spray the cells onto wounds. That method is a marked improvement over pump spray devices, which create high-pressure forces behind a narrow aperture, exposing fragile cells to thrashing that is more likely to cause damage.
Scientists at BCRT also will study various additional features and behaviors related to skin stem cells and their ability to replicate and grow, for wound healing.